# China NMPA Drug Inspection - Sichuan Zhongyong Pharmaceutical Co., Ltd. - Polygonum multiflorum vine

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/sichuan-zhongyong-pharmaceutical-co-ltd/8c5e9cc2-0e41-4e43-8f2e-915cca105e9f/
Source feed: China

> China NMPA drug inspection for Sichuan Zhongyong Pharmaceutical Co., Ltd. published November 13, 2020. Drug: Polygonum multiflorum vine. On November 13, 2020, the Chongqing Municipal Drug Administration announced that 12 batches of drugs from 11 manufacture

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Announcement from Chongqing Municipal Drug Administration Regarding 12 Batches of Drugs That Failed to Meet Regulations
- Company Name: Sichuan Zhongyong Pharmaceutical Co., Ltd.
- Publication Date: 2020-11-13
- Drug Name: Polygonum multiflorum vine
- Inspection Finding: Properties do not meet regulations
- Action Taken: The relevant authorities were instructed to take necessary control measures such as sealing up, seizing, suspending sales, and recalling products, and to investigate and handle the matter in accordance with relevant laws and regulations.
- Summary: On November 13, 2020, the Chongqing Municipal Drug Administration announced that 12 batches of drugs from 11 manufacturers failed to meet national quality standards. Affected companies include Hebei Chufeng Traditional Chinese Medicine Pieces Co., Ltd., Sichuan Shengshi Jinrong Pharmaceutical Co., Ltd., Shanxi Fenhe Pharmaceutical Co., Ltd., and several others specializing in traditional Chinese medicine. The inspections, conducted by various regional testing institutes, found that products like Isatis Root, Cassia Seed, and Vitamin U Belladonna Aluminum Capsules did not comply with the Chinese Pharmacopoeia 2015 Edition. The main violations included failures in content determination (active ingredient levels), incorrect botanical identification, and substandard physical properties, such as moldy samples and improper appearance. In response, the Chongqing Municipal Drug Administration has ordered the immediate sealing, seizure, and recall of all non-compliant products. Sales of these batches must be suspended, and the companies involved face formal investigations to ensure compliance with drug safety laws. Notably, several manufacturers have denied producing the specific batches identified in the report, suggesting potential supply chain issues.

Company: https://www.globalkeysolutions.net/companies/sichuan-zhongyong-pharmaceutical-co-ltd/bd82e2bc-1203-4c01-ab5c-bef65699beac/